Gainers

• Capricor Therapeutics (NASDAQ:CAPR) stock moved upwards by 333.2% to $27.55 during Wednesday's regular session. The company's market cap stands at $290.7 million.
• Virax Biolabs Group (NASDAQ:VRAX) shares moved upwards by 52.73% to $0.6. The company's market cap stands at $1.7 million.
• MapLight Therapeutics (NASDAQ:MPLT) stock increased by 31.96% to $17.01. The company's market cap stands at $534.0 million.
• Aardvark Therapeutics (NASDAQ:AARD) shares rose 22.81% to $11.37. The market value of their outstanding shares is at $201.6 million.
• Q/C Technologies (NASDAQ:QCLS) stock increased by 22.18% to $4.13. The company's market cap stands at $14.0 million.
• KalVista Pharmaceuticals (NASDAQ:KALV) stock increased by 19.82% to $16.2. The market value of their outstanding shares is at $683.3 million.

Losers

• ADC Therapeutics (NYSE:ADCT) shares decreased by 32.8% to $3.09 during Wednesday's regular session. The company's market cap stands at $569.8 million.
• Aethlon Medical (NASDAQ:AEMD) shares decreased by 24.18% to $3.67. The market value of their outstanding shares is at $3.6 million.
• CEL-SCI (AMEX:CVM) shares declined by 19.77% to $5.56. The company's market cap stands at $47.6 million.
• Black Diamond Therapeutic (NASDAQ:BDTX) stock decreased by 17.54% to $2.85. The company's market cap stands at $196.4 million.
• Aspire Biopharma Hldgs (NASDAQ:ASBP) shares fell 16.52% to $0.08. The market value of their outstanding shares is at $10.7 million.
• Mobile-health Network (NASDAQ:MNDR) shares declined by 14.61% to $1.93. The company's market cap stands at $3.2 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

This article was generated by Benzinga's automated content engine and reviewed by an editor.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.